PeopleRevelation Biosciences, Inc.Revelation Biosciences grants restricted stock to CEO and CFO tied to market cap goalsThe awards to James Rolke and Chester S. Zygmont, III vest in tranches as the company's market capitalization hits set thresholds or fixed anniversary dates pass.SEC filing
Quarterly updateRevelation Biosciences, Inc.Revelation Biosciences reports Q2 2026 results, advances AKI trial prepThe company said start-up activities for its Phase 2/3 acute kidney injury trial of Gemini continue, with enrollment targeted to begin by year-end.SEC filing
PeopleRevelation Biosciences, Inc.Revelation Biosciences adopts stockholder rights planThe San Diego biotech's board issued a "poison pill" triggered by 10% ownership stakes, with rights expiring in one to three years absent redemption.SEC filing
